• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Additive Manufacturing (AM)

Additive Manufacturing (AM)

AM showcases the latest technology and industry developments with in-depth case studies, resources, interviews with experts and events.

    • CHANNEL
      • Aerospace
      • Automotive
      • Energy
      • Medical
      • Innovation
    • TOPICS
      • Design
      • Management
      • Materials
      • Post Processing
      • Processes
      • Quality Management Systems
      • Regulatory & Standards
      • Software
      • Workforce Development
    • NEWS
    • EVENTS
      • Conferences
      • Virtual Events
      • Webinars
      • Industry Events
      • On-Demand
      • Add Your Event
    • MEDIA
      • AM News LIVE
      • AM Voices
      • Podcast
      • Video
    • RESOURCES

    Dassault Systèmes and the FDA Extend Collaboration to Inform Cardiovascular Device Review Process and Accelerate Access to New Treatments

    Image courtesy of Dassault Systèmes

     

    An in silico clinical trial is underway with the 3DEXPERIENCE platform to evaluate the Living Heart simulated 3D heart for transforming how new devices can be tested 

    Five-year extension of their collaborative research agreement aims to spur medical device innovation by enabling innovative, new product designs 

    Both Dassault Systèmes and the FDA recognize the transformative impact of modeling and simulation on public health and patient safety 

    VELIZY-VILLACOUBLAY, France — July 24, 2019 — Dassault Systèmes (Euronext Paris: #13065, DSY.PA) today announced the five-year extension of its collaboration with the U.S. Food and Drug Administration. The 3DEXPERIENCE platform will be used to develop a new digital tool to enable more efficient regulatory review of cardiovascular and medical devices.  Researchers hope the first-of-its-kind process will increase industry innovation and pave the way for an efficient path for patients to access safe, effective new treatments for the world’s leading cause of death – heart disease.

    This second phase of their ongoing collaboration supports the 21st Century Cures Act, using virtual patients based on computational modeling and simulation to improve efficiency of clinical trials for new device designs.  A groundbreaking project with the Living Heart simulated 3D heart model will examine the use of heart simulation as a source of digital evidence for new cardiovascular device approvals. This includes an in silico clinical trial aimed to reduce animal testing or the number of patients required while still ensuring safety and efficacy of the device is demonstrated.  The new digital process is intended to be more efficient and less expensive than current ones – whose delays and costs can impede patient access to novel treatments – without losing rigor or confidence in a device’s safety and efficacy. 

    The FDA has publicly recognized the public health benefits offered by modeling and simulation, and the potential for in silico clinical trials to safely advance medical products more efficiently, from preclinical studies through clinical trials to market.  

    “Modeling and simulation can help to inform clinical trial designs, support evidence of effectiveness, identify the most relevant patients to study, and assess product safety. In some cases, in silico clinical trials have already been shown to produce similar results as human clinical trials,” said Tina Morrison, Ph.D., Deputy Director in the Division of Applied Mechanics, Office of Science and Engineering Labs, Center for Devices and Radiological Health, FDA.  “The FDA continues to encourage research to facilitate the introduction of safe and effective therapeutic solutions.” 

    “Our collaboration with the FDA underscores the relevance and sustainability of digital twin experiences created with the 3DEXPERIENCE platform to test devices and drugs in scientific and medical innovation,” said Claire Biot, Vice President, Life Sciences Industry, Dassault Systèmes.  “Enriching technology already well established in regulated industries such as aerospace and automotive, virtual patients support the complex development of therapies for the heart, brain and more by eliminating traditional cost and time bottlenecks. With this new review process, Dassault Systèmes and the FDA can be partners in the transformative impact of the virtual world on industrial innovation, new treatments and the patient experience.”

    About Dassault Systèmes
    Dassault Systèmes, the 3DEXPERIENCE Company, provides business and people with virtual universes to imagine sustainable innovations. Its world-leading solutions transform the way products are designed, produced, and supported. Dassault Systèmes’ collaborative solutions foster social innovation, expanding possibilities for the virtual world to improve the real world. The group brings value to over 250, 000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com

    3DEXPERIENCE, the Compass logo and the 3DS logo, CATIA, SOLIDWORKS, ENOVIA, DELMIA, SIMULIA, GEOVIA, EXALEAD, 3D VIA, BIOVIA, NETVIBES and 3DEXCITE are registered trademarks of Dassault Systèmes or its subsidiaries in the US and/or other countries.

    Source: Dassault Systèmes

    related /

  • Triastek and Siemens Announce Strategic Collaboration to Accelerate Digital Transformation of the Pharmaceutical Industry
  • Filed Under: Medical, News Tagged With: 3DEXPERIENCE platform, Dassault Systèmes, U.S. Food and Drug Administration.

    Primary Sidebar

    events /

    upcoming webinars /

    • There are no upcoming events.

    on demand /

    • SOLIDWORKS Certification Tips and Tricks

      January 24 @ 11:00 am - 12:00 pm EST
    • Is there really a use for additive manufacturing in commercial vehicles?

      December 7, 2022 @ 1:00 pm - 2:00 pm EST
    • Development of Metal Additive Manufacturing for Naval Shipbuilding

      December 1, 2022 @ 1:00 pm - 2:00 pm EST

    Footer

    AM-logo_RGB_500_white

    With dozens of innovative products, materials, software, and applications being launched constantly, you can rely on AdditiveManufacturing.com to keep you ahead of the curve.

    stay connected /

    recent /

    • Watch On-Demand: AM News LIVE: EP22 – Anne Pauley & Michael Molitch-Hou – CES, TIPE, AMS – Monday, January 23rd 2023
    • Workforce and Leadership: AM News Roundup for January 9-20, 2023
    • Dennis Fehr, Seasoned Financial Executive Joins 6K as Chief Financial Officer and Rob Davies, Manufacturing Expert, Joins 6K Energy as Chief Operating Officer
    • BIRD – Israel-U.S. Binational Industrial R&D Foundation to invest $8.4 million in 9 new projects
    • Epredia and Aiforia Join RegenMed Hub Innovation Accelerator, Expanding PHC Group Presence in Regenerative Medicine
    • IperionX Wins U.S. Air Force Titanium Recycling Challenge
    • Essentium Expands Global Executive Leadership
    • Student Team Uses Micro Metal 3D Printing for Microgravity Experiment

    topics /

    • Applications
    • Design
    • Materials
    • Post Processing
    • Processes
    • Quality Management Systems
    • Regulatory & Standards
    • Software

    media /

    • Watch On-Demand: AM News LIVE: EP22 – Anne Pauley & Michael Molitch-Hou – CES, TIPE, AMS – Monday, January 23rd 2023
    • AM Materials Chat: 6K onsite at Formnext 2022 – AM Voices Podcast – Frank Roberts, President of 6K Additive
    • Watch On-Demand: AM News LIVE: EP21 – Sintavia – Brian R. Neff – Monday, January 9th 2023
    • Formnext 2022 flashback: Uniformity Labs, CEO Adam Hopkins on LPBF materials for 3D printing
    • AM Materials Chat: Uniformity Labs onsite at Incodema3D – AM Voices video podcast – Adam Hopkins, CEO at Uniformity Labs
    • AM Materials Chat: Elementum3D onsite at Incodema3D for AM Voices video podcast
    • AM Video Interview: Dr. Jason Rolland, SVP of Materials at Carbon
    • Watch On-Demand: AM News LIVE, EP20 – End Of Year Episode – 2022 Review with Friends

    Copyright © 2023 Metrix Connect, LLC

    • Advertise
    • About Us
    • Privacy Policy
    • Terms of Use
    • Editorial Guidelines
    • Code of Conduct
    • Contact